Docusign Envelope ID: 330FA79F-65F4-45AC-B35F-F4AF131E45D0
Annual report 30/12/2025
## ANNUAL REPORT 2024
## DETAILS
Antivenom Foundation Reg: 1204543 Period start 24/12/2024 Period end 30/12/2025
## INTRODUCTION
Snakebite envenoming alone kills an estimated 81,000–138,000 people every year and leaves over 400,000 survivors with permanent disabilities, according to the World Health Organization. Other venomous animals—such as scorpions, spiders, and marine species— can also cause significant harm, particularly in rural and resource-limited settings. The only effective treatment for envenoming is antivenom, but it is difficult to produce, expensive, and often unavailable in regions that need it most. Many areas suffer chronic shortages or have no coverage at all, leaving vulnerable communities without life-saving antidotes.
This year marked another step forward as we continued laying the foundations for our long-term mission to improve access to effective antivenoms in regions where envenomation remains a critical public health challenge. While we are still in the early stages, our efforts have focused on supporting research, regulatory submissions, and building partnerships that will lay the ground for the future.
## OBJECTIVES AND ACTIVITIES
## Summary of charity purpose
The primary aim of the Antivenom Foundation is to establish the world’s first international antivenom stockpile mechanism, ensuring timely access to effective treatments that prevent death and disability caused by bites and stings from venomous animals. In pursuit of this goal, the foundation also works to support patients, physicians, and local organizations, while advancing research, education, and awareness on the issue of animal envenomation.
## Summary of main activities
Our goal is ambitious, and we are only at the beginning of what will be a long and challenging journey. In this second year of activity, the foundation has built on last year’s progress by
supporting initial safety studies in Lebanon, preparing submissions for antivenom approval in subSaharan Africa, expanding our network of international experts, and contributing to education and knowledge-sharing initiatives.
## Statement on Charity commission guidance on public benefit
The Trustees confirm that, in exercising their powers and duties, they have had due regard to the guidance on public benefit issued by the Charity Commission for England and Wales. The Trustees
Docusign Envelope ID: 330FA79F-65F4-45AC-B35F-F4AF131E45D0
Annual report 30/12/2025
are satisfied that the charity's activities have been carried out in a manner that aligns with the public benefit requirement set out in the Charity Commission’s guidelines.
In making decisions, the Trustees have considered both the aims and the activities of the charity, ensuring that they are for the public benefit and that the charity's resources are used effectively to further its charitable purposes.
## ACHIEVEMENTS AND PERFORMANCE
## Summary of main achievements
As with the previous year our main achievements in this period have come from the ability of the foundation to draw on a network of international expert volunteers providing small but meaningful contributions that have made a significant difference on the ground.
Sub-Saharan Africa: Our experts continued to assist the University of Costa Rica with regulatory submissions for antivenom in sub-Saharan Africa—a major focus that required significant time and expertise. As part of this effort, we collaborated with local partners in Eswatini to collect and analyse data from their sucessfull implementation of a new antivenom. Regulatory documents are now ready for submission to the local authorities, pending completion of refurbishments at the production plant to allow inspection.
Regional networks: We strengthened engagement with medical toxicology networks across subSaharan Africa, and the MENA region with our volunteers invited to join key expert groups. This is an important step toward understanding challenges on the ground. Additionally, we provided speakers for educational seminars organized by local partners in Eswatini and South Africa, helping to raise awareness and share knowledge.
Levant: We provided administrative support to the American University of Beirut (AUB) for safety testing of a new antivenom formulation. This initial study was very small-scale but successful, identifying important issues related to packaging, logistics, handling, and study design that need resolution before larger trials can proceed. With limited effective antivenoms available for the region, we understand that larger humanitarian organizations are now exploring ways to advance this work as they are desperately in need of an effective antivenom for this region.
## FINANCIAL REVIEW
## Review of financial position
The Antivenom Foundation is still a start-up charity in the process of setting up, it therefore has not undertaken any substantial fundraising or activities that incurred any expense. Thanks to donation platforms we raised more funds than last year—though still very modest, these resources are being held in reserve until we have sufficient capital to undertake more substantial projects.
Docusign Envelope ID: 330FA79F-65F4-45AC-B35F-F4AF131E45D0
Annual report 30/12/2025
## Reserves policy
Currently the foundation has no formal reserves policy as we have been focused on supporting activities and have not raised significant funds or incurred any overheads. Should this position change in the future then the trustees will develop a reserves policy as appropriate.
## Going concerns
The economic environment continues to present challenges for the charity sector, particularly for start-up organisations like ours. Opportunities for grant funding remain limited, and our international focus on neglected diseases further narrows the pool of potential donors. Antivenom is inherently expensive, meaning substantial funds will need to be raised before we can begin fulfilling our primary objective of providing antivenom to those in need.
Despite these challenges, the foundation operates with minimal overheads and currently incurs no significant expenses. We continue to provide a valuable nucleus that connects local organizations with global experts, enabling progress in research, regulatory processes, and knowledge sharing. While fundraising remains difficult and current reserves are modest, the foundation benefits from a committed team of volunteers who are prepared for the long journey ahead.
For these reasons, the trustees remain confident in the charity’s ability to continue operating and advancing its mission over the coming year.
## STRUCTURE, GOVERNANCE AND MANAGEMENT
The Antivenom Foundation is a Charitable Incorporated Organisation (CIO) governed by constitution. Trustees are appointed for a term of 3 years by majority resolution passed at a properly convened meeting of the charity trustees. In selecting individuals for appointment as charity trustees, the charity trustees must have regard to the skills, knowledge and experience needed for the effective administration of the CIO.
## REFERENCE AND ADMINISTRATIVE DETAILS
Antivenom Foundation (AVF) Reg: 1204543 Address 11 Spring Grove Godalming GU7 3SS
Trustees Active from Term Faisa Price 31/8/2023 4 years Steven Swallow 31/8/2023 3 Years Alessia Cacioni 7/01/2024 3 years
Docusign Envelope ID: 330FA79F-65F4-45AC-B35F-F4AF131E45D0
Annual report 30/12/2025
FUNDS HELD AS CUSTODIAN TRUSTEES ON BEHALF OF OTHERS
Not applicable
## DECLARATIONS
The trustees declare that they have approved the trustees’ report above.
Trustee: Faisa Price Trustee: Steven Swallow Signed: Signed:
|**Antivenom Foundation**|**Antivenom Foundation**|**Antivenom Foundation**|**1204543**|
|---|---|---|---|
|**Receipts andpayments accounts**||||
|**For the period**
**from**|12/24/24|**To**|12/30/25|
**For the period** 12/24/24 **from**
12/30/25
**To**
## **CC16a**
## **Section A Receipts and payments**
|**A1 Receipts**|**Unrestricted**
**funds**
**to the nearest £**
**3,617**
**157**
**-**
**-**
**-**
**-**
**-**
**-**
**3,774**
**-**
**-**
**-**
**3,774**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**3,774**
**-**
**-**
**3,774**|**Restricted**
**funds**
**to the nearest £**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**|**Endowment**
**funds**
**to the nearest £**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**|**Total funds**
**to the nearest £**
**3,617**
**157**
**-**
**-**
**-**
**-**
**-**
**-**
**3,774**
**-**
**-**
**-**
**3,774**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**3,774**|**Total funds**
**to the nearest £**
**3,617**
**157**
**-**
**-**
**-**
**-**
**-**
**-**
**3,774**
**-**
**-**
**-**
**3,774**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**3,774**|**Last year**
**to the nearest £**|
|---|---|---|---|---|---|---|
|Donations|**3,617**|||||**157**|
|Cash reserve frompreviousyear|**157**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
|**_Sub total_**_(Gross income for_
_AR)_|
**3,774**|||||**157**|
||||||||
|**A2 Asset and investment sales,**
**(see table).**|||||||
||**-**||||||
||**-**|||||**-**|
|~~**_Sub total_**~~|**-**|||||**-**|
|**_Total receipts_ **
**A3 Payments**|||||||
|||||||**157**|
||||||||
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
|**_Sub total_ **|**-**|||||**-**|
||||||||
|**A4 Asset and investment**
**purchases, (see table)**|||||||
||**-**||||||
||**-**||||||
|**_Sub total_ **|**-**|||||**-**|
|**_Total payments_**
**_Net of receipts/(payments)_**
**A5 Transfers between funds**
**A6 Cash funds last year end**
**_Cash funds this year end_**|||||||
|||||||**-**|
||||||||
||**3,774**|**-**|**-**|**3,774**||**157**|
||**-**|**-**|**-**|**-**||**-**|
||**-**|**-**|**-**|**-**||**-**|
||**3,774**|**-**|**-**|**3,774**||**157**|
CCXX R1 accounts (SS)
30/12/2025
1
|**Section B Statement of assets and liabilities at**|**Section B Statement of assets and liabilities at**|**the end of the period**||
|---|---|---|---|
|**Categories**
Signed by one or two trustees on
behalf of all the trustees
**B1 Cash funds**
**B2 Other monetary assets**
**B4 Assets retained for the**
**charity’s own use**
**B5 Liabilities**
**B3 Investment assets**|Signature
Donations
Cash reserve from previous year
**Details**
**_Total cash funds_**
(agree balances with receipts and payments
account(s))
**Details**
**Details**
**Details**
**Details**|**Unrestricted**
**funds**
**Restricted**
**funds**
**to nearest £**
**to nearest £**
**3,617**
**-**
**157**
**-**
**-**
**-**
**3,774**
**-**
OK
OK
**Unrestricted**
**funds**
**Restricted**
**funds**
**to nearest £**
**to nearest £**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**Fund to which**
**asset belongs**
**Cost (optional)**
**-**
**-**
**-**
**-**
**-**
**Fund to which**
**asset belongs**
**Cost (optional)**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**Fund to which**
**liability relates**
**Amount due**
**(optional)**
**-**
**-**
**-**
**-**
**-**
Print Name
Faisa Price|**Endowment**
**funds**
**to nearest £**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||OK|
||||**Endowment**
**funds**
**to nearest £**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**Current value**
**(optional)**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**Current value**
**(optional)**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**When due**
**(optional)**|
|||||
|||||
|||||
|||||
|||||
|||||
||||Date of
approval|
|||Faisa Price|30/12/2025|
|||||
CCXX R2 accounts (SS)
30/12/2025
2